Teva Reports Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Teva Pharma (TEVA) Misses Q3 EPS by 1c, Updates FY Guidance
November 7, 2019 7:05 AM ESTTeva Pharma (NYSE: TEVA) reported Q3 EPS of $0.58, $0.01 worse than the analyst estimate of $0.59. Revenue for the quarter came in at $4.3 billion versus the consensus estimate of $4.23 billion.
GUIDANCE:
Teva Pharma sees FY2019 EPS of $2.30-$2.50, versus the consensus of... More
